Chimeric Therapeutics jumps most in 3 weeks on cell therapy study progress

Chimeric Therapeutics

22/12/2022 03:25

** Shares of biotech firm Chimeric Therapeutics  CHM.AX  jump as
much as 6.5% to A$0.082
    ** Co says it has completed the planned dosing for patients
in the third cohort under phase 1 study for its cell therapy
drug currently being developed  urn:newsml:reuters.com:*:nASX77gN7B
    ** Shares on track for their biggest pct gain since Dec. 1 
    ** Stock down 69.3% this year as of last close, vs a 4.4%
decrease in the benchmark S&P/ASX 200 index  .AXJO  
 (Reporting by Roushni Nair in Bengaluru)
 ((Roushni.Nair@thomsonreuters.com;))